# Plexium

> Plexium is a San Diego precision medicine company designing small-molecule protein degraders - monovalent direct degraders and molecular glues - that switch off disease-driving proteins traditionally considered undruggable. Its DELTA Discovery platform runs ultra-high-throughput cell-based screening to find and optimize new degrader chemistry across cancer and neurological disease.

- **Founded:** 2017
- **Headquarters:** San Diego, United States
- **Founders:** Andrew MacConnell (Co-founder), Joe Rokicki (Co-founder), Kandaswamy 'Swamy' Vijayan (Founder, former CEO)
- **Team size:** approx. 44 employees
- **Products:** DELTA Discovery Platform, PLX-4545, Monovalent Direct Degraders, Molecular Glue Discovery
- **Notable:** Raised ~$225M total since 2019, Signed Amgen deal worth up to $500M in 2022, Inked exclusive AbbVie partnership in neuroscience

## Products & services

- **DELTA Discovery Platform** — Proprietary ultra-high-throughput cell-based screening platform that interrogates millions of compounds in disease-relevant cells to identify protein degraders.
- **PLX-4545** — Oral CRBN-based molecular glue degrader of IKZF2, currently advancing past phase 1 in healthy volunteers toward oncology patient studies.
- **Monovalent Direct Degraders** — A class of cell-permeable small molecules that recruit E3 ligases to destroy a target protein without the bulk of bifunctional PROTACs.
- **Molecular Glue Discovery** — Rational design of small molecules that stabilize new protein-protein interactions and induce target degradation.

## Achievements

- Raised ~$225M total since 2019
- Signed Amgen deal worth up to $500M in 2022
- Inked exclusive AbbVie partnership in neuroscience
- Advanced PLX-4545 through phase 1 in healthy volunteers
- Built DELTA Discovery, a proprietary ultra-high-throughput cell-based screening platform

## Latest updates

- **2025-08** — Raised $60.1M to extend runway and advance pipeline.
- **2025-08** — Amgen collaboration concluded; AbbVie partnership continues.
- **2024-01** — Appointed Michael Martin, Ph.D. as President and CEO.
- **2022-02** — Closed $102M Series C led by SoftBank Vision Fund 2.

## Links

- Website: https://plexium.com
- LinkedIn: https://www.linkedin.com/company/plexium
- Twitter/X: https://twitter.com/PlexiumTx
- Facebook: https://facebook.com/Plexium-102140614535000

---

Profile page: https://yespress.io/plexium
Published by YesPress — https://yespress.io
Last updated: 2026-06-28